CY1109784T1 - Υποκατεστημενα γλουταριμιδια και η χρησιμοποιηση τους σαν αναστολεις της il-12 παραγωγης - Google Patents
Υποκατεστημενα γλουταριμιδια και η χρησιμοποιηση τους σαν αναστολεις της il-12 παραγωγηςInfo
- Publication number
- CY1109784T1 CY1109784T1 CY20101100143T CY101100143T CY1109784T1 CY 1109784 T1 CY1109784 T1 CY 1109784T1 CY 20101100143 T CY20101100143 T CY 20101100143T CY 101100143 T CY101100143 T CY 101100143T CY 1109784 T1 CY1109784 T1 CY 1109784T1
- Authority
- CY
- Cyprus
- Prior art keywords
- inhibitors
- cr8r9
- group
- substituted glutarimides
- stands
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
Abstract
Περιγράφονται υποκατεστημένα γλουταριμίδια του τύπου (I), στον οποίο Χ σημαίνει μία ομάδα του τύπου (CH2)n-(CR8R9)p-Z-(CR8R9)m, Ζ στέκει για άτομο θείου ή οξυγόνου, την ομάδα SO- ή SO2, την ρίζα NR8 (ενδεχομένως στη μορφή του Ν-οξειδίου) ή μία ομάδα CR8R9, m και p στέκουν για 0 ή 1, n για 1, 2 ή 3, όπου m, n και p δεν μπορούν να είναι ταυτόχρονα 0, η παρασκευή τους και η χρησιμοποίησή τους σε φάρμακα, ειδικότερα σαν ανοσοδιαμορφωτές καθώς και σαν αναστολείς για αγγειοπάθειες και/ή αιματολογικές/ογκολογικές ασθένειες.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10002509A DE10002509A1 (de) | 2000-01-21 | 2000-01-21 | Substituierte Glutarimide |
| EP01900400A EP1252144B1 (de) | 2000-01-21 | 2001-01-09 | Substituierte glutarimide und ihre verwendung als inhibitoren der il-12 produktion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109784T1 true CY1109784T1 (el) | 2014-09-10 |
Family
ID=7628270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100143T CY1109784T1 (el) | 2000-01-21 | 2010-02-11 | Υποκατεστημενα γλουταριμιδια και η χρησιμοποιηση τους σαν αναστολεις της il-12 παραγωγης |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US6656937B2 (el) |
| EP (1) | EP1252144B1 (el) |
| JP (1) | JP2003524641A (el) |
| KR (1) | KR20020067614A (el) |
| CN (1) | CN1185215C (el) |
| AR (1) | AR030185A1 (el) |
| AT (1) | ATE451355T1 (el) |
| AU (1) | AU780636B2 (el) |
| BR (1) | BR0108030A (el) |
| CA (1) | CA2398061A1 (el) |
| CO (1) | CO5261626A1 (el) |
| CY (1) | CY1109784T1 (el) |
| DE (2) | DE10002509A1 (el) |
| DK (1) | DK1252144T3 (el) |
| ES (1) | ES2337875T3 (el) |
| HU (1) | HUP0204235A3 (el) |
| IL (1) | IL150813A0 (el) |
| MX (1) | MXPA02007089A (el) |
| NO (1) | NO323395B1 (el) |
| NZ (1) | NZ520759A (el) |
| PE (1) | PE20011067A1 (el) |
| PL (1) | PL356986A1 (el) |
| PT (1) | PT1252144E (el) |
| RU (1) | RU2278857C2 (el) |
| SI (1) | SI1252144T1 (el) |
| SK (1) | SK287173B6 (el) |
| WO (1) | WO2001053261A1 (el) |
| ZA (1) | ZA200206664B (el) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10002509A1 (de) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
| US7842727B2 (en) | 2001-03-27 | 2010-11-30 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| DE10163595A1 (de) | 2001-12-21 | 2003-08-07 | Gruenenthal Gmbh | In 3-Position heterocyclisch substituierte Piperidin-2,6-dione |
| CA2486303C (en) | 2002-05-22 | 2013-04-30 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds |
| AU2003243285A1 (en) * | 2002-05-22 | 2003-12-12 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds |
| US20040192738A1 (en) * | 2003-03-18 | 2004-09-30 | Aventis Pharma Deutschland Gmbh | 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it |
| ATE533745T1 (de) | 2004-03-17 | 2011-12-15 | Pfizer Prod Inc | Neue benzyl(iden)-lactam-derivate |
| DE102004026703A1 (de) * | 2004-05-28 | 2005-12-29 | Grünenthal GmbH | Verfahren zur Herstellung von in 3-Position heterocyclisch substituierten Piperidin-2,6-dionen |
| WO2014107622A1 (en) | 2013-01-07 | 2014-07-10 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| US9815814B2 (en) * | 2013-04-12 | 2017-11-14 | Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
| JP6513095B2 (ja) | 2014-01-03 | 2019-05-15 | ユニバーシティ オブ サザン カリフォルニア | ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤 |
| US10577321B2 (en) | 2015-07-08 | 2020-03-03 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| US10544105B2 (en) | 2015-07-08 | 2020-01-28 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
| EP3319939A1 (en) | 2015-07-08 | 2018-05-16 | CV6 Therapeutics (NI) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| RU2610275C2 (ru) * | 2015-07-30 | 2017-02-08 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения |
| US11395820B2 (en) * | 2016-03-16 | 2022-07-26 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Small molecules against cereblon to enhance effector t cell function |
| WO2018098206A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US10829457B2 (en) | 2016-11-23 | 2020-11-10 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
| US11168059B2 (en) | 2016-11-23 | 2021-11-09 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
| WO2018098207A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US11174271B2 (en) | 2016-11-23 | 2021-11-16 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
| US11247984B2 (en) | 2017-01-05 | 2022-02-15 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
| EA201992341A8 (ru) * | 2017-09-07 | 2020-08-11 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов |
| IL273432B (en) | 2017-09-22 | 2022-09-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
| EP3684366A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES OF THE LATEST |
| SG11202005912PA (en) | 2017-12-26 | 2020-07-29 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| CN107903245B (zh) * | 2018-01-15 | 2018-11-13 | 青岛大学附属医院 | 一种化合物及其在制备治疗类风湿性关节炎药物中的应用 |
| CN107857754B (zh) * | 2018-01-15 | 2018-11-09 | 泰山医学院 | 一种化合物及其在制备预防/治疗类风湿性关节炎药物中的应用 |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| US11730726B2 (en) | 2018-07-11 | 2023-08-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Dimeric immuno-modulatory compounds against cereblon-based mechanisms |
| US11352350B2 (en) | 2018-11-30 | 2022-06-07 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| MA55565A (fr) | 2019-04-05 | 2022-02-09 | Kymera Therapeutics Inc | Agents de dégradation de stat et leurs utilisations |
| BR112022011651A2 (pt) | 2019-12-17 | 2022-08-23 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| TW202136242A (zh) | 2019-12-23 | 2021-10-01 | 美商凱麥拉醫療公司 | Smarca降解劑及其用途 |
| JP2023518423A (ja) | 2020-03-19 | 2023-05-01 | カイメラ セラピューティクス， インコーポレイテッド | Ｍｄｍ２分解剤およびそれらの使用 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| BR112022026356A2 (pt) * | 2020-06-26 | 2023-01-17 | Valenta Intellekt Ltd | Uso de um derivado de glutarimida para tratar doenças associadas à atividade aberrante da interleucina-6 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2673205A (en) * | 1951-02-13 | 1954-03-23 | Ciba Pharm Prod Inc | 3-disubstituted dioxopiperidines and the manufacture thereof |
| US3214431A (en) * | 1958-08-04 | 1965-10-26 | Pfizer & Co C | Novel glutarimides |
| US5114937A (en) * | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
| GB8928043D0 (en) * | 1989-12-12 | 1990-02-14 | Pfizer Ltd | Muscarinic receptor antagonists |
| FR2745811B1 (fr) * | 1996-03-07 | 1998-05-22 | Sanofi Sa | Glutarimide disubstitue procede pour sa preparation, et son utilisation |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| DE19703763C1 (de) * | 1997-02-01 | 1998-10-01 | Gruenenthal Gmbh | Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione |
| DE19843793C2 (de) * | 1998-09-24 | 2000-08-03 | Gruenenthal Gmbh | Substituierte Benzamide |
| DE10002509A1 (de) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
-
2000
- 2000-01-21 DE DE10002509A patent/DE10002509A1/de not_active Ceased
-
2001
- 2001-01-09 DK DK01900400.1T patent/DK1252144T3/da active
- 2001-01-09 JP JP2001553265A patent/JP2003524641A/ja not_active Withdrawn
- 2001-01-09 HU HU0204235A patent/HUP0204235A3/hu unknown
- 2001-01-09 MX MXPA02007089A patent/MXPA02007089A/es active IP Right Grant
- 2001-01-09 KR KR1020027009243A patent/KR20020067614A/ko not_active Application Discontinuation
- 2001-01-09 EP EP01900400A patent/EP1252144B1/de not_active Expired - Lifetime
- 2001-01-09 PL PL01356986A patent/PL356986A1/xx not_active Application Discontinuation
- 2001-01-09 BR BR0108030-0A patent/BR0108030A/pt not_active IP Right Cessation
- 2001-01-09 SI SI200130961T patent/SI1252144T1/sl unknown
- 2001-01-09 NZ NZ520759A patent/NZ520759A/en unknown
- 2001-01-09 AT AT01900400T patent/ATE451355T1/de not_active IP Right Cessation
- 2001-01-09 RU RU2002121641/04A patent/RU2278857C2/ru not_active IP Right Cessation
- 2001-01-09 AU AU25140/01A patent/AU780636B2/en not_active Ceased
- 2001-01-09 ES ES01900400T patent/ES2337875T3/es not_active Expired - Lifetime
- 2001-01-09 IL IL15081301A patent/IL150813A0/xx unknown
- 2001-01-09 SK SK1017-2002A patent/SK287173B6/sk not_active IP Right Cessation
- 2001-01-09 PT PT01900400T patent/PT1252144E/pt unknown
- 2001-01-09 DE DE50115252T patent/DE50115252D1/de not_active Expired - Lifetime
- 2001-01-09 CN CNB018038883A patent/CN1185215C/zh not_active Expired - Fee Related
- 2001-01-09 WO PCT/EP2001/000155 patent/WO2001053261A1/de active IP Right Grant
- 2001-01-09 CA CA002398061A patent/CA2398061A1/en not_active Abandoned
- 2001-01-19 CO CO01003816A patent/CO5261626A1/es not_active Application Discontinuation
- 2001-01-19 PE PE2001000061A patent/PE20011067A1/es not_active Application Discontinuation
- 2001-01-19 AR ARP010100251A patent/AR030185A1/es unknown
-
2002
- 2002-07-09 NO NO20023319A patent/NO323395B1/no not_active IP Right Cessation
- 2002-07-19 US US10/198,073 patent/US6656937B2/en not_active Expired - Fee Related
- 2002-08-20 ZA ZA200206664A patent/ZA200206664B/en unknown
-
2003
- 2003-09-03 US US10/653,188 patent/US20040048859A1/en not_active Abandoned
-
2010
- 2010-02-11 CY CY20101100143T patent/CY1109784T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109784T1 (el) | Υποκατεστημενα γλουταριμιδια και η χρησιμοποιηση τους σαν αναστολεις της il-12 παραγωγης | |
| ATE515277T1 (de) | Zusammensetzungen und verfahren zum beschichten von medizinischen implantaten | |
| ATE447561T1 (de) | Substituierte aryl 1,4-pyrazin derivate | |
| CY1108306T1 (el) | Αναστολεις αζαϊνδολιου των mtp και apob | |
| NO20161012A1 (no) | Farmasøytisk sammensetning omfattende polymorfe former av 3-(4-amino-1-okso-1,3-dihydro-isoindol-2-yl)-piperidin-1,6-dion | |
| ATE481093T1 (de) | Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit | |
| CY1106532T1 (el) | Ετερολογος εκφραση των πρωτεϊνων της neisseria | |
| CY1113312T1 (el) | Κυκλικοι αναστολεις κινασης τυροσινης πρωτεϊνων | |
| NO20005224L (no) | BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse | |
| CY1112687T1 (el) | Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες | |
| CY1105286T1 (el) | Ω-καρβοξυαρυλυποκατεστημενες διφαινυλουριες σαν αναστολεις της raf κινασης | |
| DK1200418T3 (da) | Nematodicide trifluorbutener | |
| CY1108754T1 (el) | Νεα παραγωγα θειοφαινογλυκοσιδης, μεθοδος για την παρασκευη τους, φαρμακα περιεχοντα αυτες τις ενωσεις και η χρηση τους | |
| ATE350409T1 (de) | Ampholytisches copolymer und dessen verwendung | |
| NO20064547L (no) | Fremgangsmater for behandling av HIV infeksjon | |
| NO20040845L (no) | Substituerte indeno[1,2-c]isokinolinderivater og deres anvendelse | |
| CY1109465T1 (el) | Νεες φαρμακευτικες φαρμακοτεχνικες μορφες μονταφινιλης | |
| DK0842934T3 (da) | 5-HT1F agonister | |
| NO990662L (no) | Trombin-inhibitorer | |
| DK1313740T3 (da) | Prodrugs af imidazopyridinderivater | |
| ATE365748T1 (de) | Polymer-konjugate von neublastin und methoden für deren verwendung | |
| ATE514087T1 (de) | Glycokonjugate und ihre verwendung als potentielle impfstoffe gegen eine infektion mit shigella flexneri | |
| ATE398109T1 (de) | 4-pyrimidinamine derivate, pharmazeutische zusammenstellungen und verwandte methoden | |
| DK1377574T3 (da) | 6-phenylbenzonaphtyridiner | |
| CY1106540T1 (el) | Ετεροκυλικα υποκατεστημενες στη θεση 3 πιπεριδινο-2,6-διονες |